Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine

Post time 3 day(s) ago

journal：Clinical Cancer Research

Authors：Evan C. Chen; Yiwen Liu; Hayden L. Bell; Jeremy Ryan; Jason Wu; Emma-Jayne Minihane; Marlise R. Luskin; Eric S. Winer; Rahul Vedula; Virginia Volpe; Maximilian Stahl; Daniel Roberts; Ilene Galinsky; Mary Gerard; Matthew Hersch; Jessica Lee; Donna Neuberg; Richard M. Stone; Daniel J. DeAngelo; Anthony Letai; Andrew A. Lane; Jacqueline S. Garcia

Published date：--

DOI：10.1158/1078-0432.ccr-25-4905

PDF link：https://aacrjournals.org/clincan ... 506/ccr-25-4905.pdf

Article link：https://doi.org/10.1158/1078-0432.ccr-25-4905

Article Source：American Association for Cancer Research (AACR)。

Remark：

Post time The day before yesterday 08:31

: Waiting for confirmation
If the PDF has not been accepted after 72 hours, the system will automatically adopt it.

[AACR] Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine

Same Category

Latest Reply

Announcement

Daily Top Contributors

[AACR] Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine Copy

Same Category

Latest Reply

Announcement

Daily Top Contributors

[AACR] Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine